Loading…
Loading…
IVBXF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for IVBXF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IVBXF and 80,000+ other tickers.
See exactly how IVBXF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IVBXF and 80,000+ other tickers.
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments. Innovent's flagship therapeutic offering is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in managing various cancers, including Hodgkin's lymphoma and esophageal carcinoma…
Innovent Biologics, Inc. and Eli Lilly and Co. (NYSE:LLY) on Tuesday entered into a distribution and promotion agreement for Eli Lilly's breast cancer therapy Verzenios (abemaciclib) in mainland China.
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tuesday.
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a a list published by the National Healthcare Security Administration showed on Monday.
SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin has completed an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds, and other institutional investors new to Ollin, including a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., and a leading sovereign wealth fund, alongside continued investment from co-founding investors Mubadala Capital and Monograph Capital.
SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the first patient has been dosed in the Chinese pivotal Phase 3 clinical trial (TriadicMM-1) of its self-developed innovative anti-GPRC5D, BCMA and CD3 tri-specific antibody IBI3003 for the second to fifth-line treatment of patients with relapsed or refractory multiple myeloma (R/R MM). IBI3003 is China's first self-developed anti-GPRC5D/BCMA/CD3 tri-specific antibody to enter the pivotal registrational Phase III clinical trial, aiming to bring a promising next-generation immunotherapy option for Chinese R/R MM patients.